Australia’s biotechnology firm CSL has completed the acquisition of global influenza vaccine business from Novartis for around $275m.
The deal was first announced by both firms in October 2014.
Go deeper with GlobalData
CSL will incorporate the acquired business in its subsidiary bioCSL, as the transaction concluded.
The combined business is claimed to be the second largest influenza vaccine business in the $4bn global industry.
With manufacturing facilities in the US, UK, Germany and Australia, the business includes differentiated product portfolio and strong pandemic and pre-pandemic franchises in around 20 countries.
According to CSL, the combined business will complete all clinical programmes underway and market all bioCSL and Novartis influenza vaccine brands in various markets.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe combined business will continue to in-licence and supply a wide range of vaccines and specialty pharmaceuticals, as well as produce blood typing reagents for local use in Australia.
It will also continue to produce anti-venoms and Q fever vaccine, claimed to be the world’s only supplier of these Australian medicines.
At the time of acquisition, bioCSL general manager Dr John Anderson said: "This will transform bioCSL’s existing influenza vaccine business, giving us first class facilities, global scale and product and geographical diversity.
"bioCSL is absolutely focused on its critical role as Australia’s onshore supplier of influenza vaccine, which underpins its pivotal position in both the nation’s influenza pandemic preparedness and swift seasonal responses to influenza."
Image: Novartis headquarters in Basel. Photo: courtesy of Andrew.
